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MacrophageWnt/β-catenin is involved in every aspect of embryonic development and in the pathogenesis of many human
diseases, and is also implicated in organﬁbrosis. However, the role ofβ-catenin-mediated signaling on liverﬁbro-
sis remains unclear. To explore this issue, the effects of PRI-724, a selective inhibitor of the cAMP-response
element-binding protein-binding protein (CBP)/β-catenin interaction, on liver ﬁbrosis were examined using car-
bon tetrachloride (CCl4)- or bile duct ligation (BDL)-induced mouse liver ﬁbrosis models. Following repetitive
CCl4 administrations, the nuclear translocation of β-catenin was observed only in the non-parenchymal cells in
the liver. PRI-724 treatment reduced the ﬁbrosis induced by CCl4 or BDL. C-82, an active form of PRI-724,
inhibited the activation of isolated primary mouse quiescent hepatic stellate cells (HSCs) and promoted cell
death in culture-activated HSCs. During the ﬁbrosis resolution period, an increase in F4/80+ CD11b+ and Ly6Clow
CD11b+ macrophages was induced by CCl4 and was sustained for two weeks thereafter, even after having
stopped CCl4 treatment. PRI-724 accelerated the resolution of CCl4-induced liver ﬁbrosis, and this was accompa-
nied by increasedmatrixmetalloproteinase (MMP)-9,MMP-2, andMMP-8 expression in intrahepatic leukocytes.
In conclusion, targeting the CBP/β-catenin interaction may become a new therapeutic strategy in treating liver
ﬁbrosis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic tissue injury leads to ﬁbrosis in many organs, including the
liver, lungs, kidneys, andheart. In chronic liver disease, the development
of ﬁbrosis is the ﬁrst step toward the progression to cirrhosis and its
complications (such as organ failure, esophageal variceal bleeding, andng protein; CBP, CREB-binding
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. This is an open access article underhepatocellular carcinoma), irrespective of the underlying etiology
(Bataller and Brenner, 2005), and there is currently no effective therapy.
Although many pathways and cytokines such as transforming growth
factor (TGF)-β, platelet-derived growth factor (PDGF), Toll-like receptor
(TLR) 4, sphingosine-1-phosphate, AKT, andp38mitogen-activated pro-
tein kinase (MAPK) have been characterized as mediators of liver ﬁbro-
sis, the underlying molecular mechanism is still not well deﬁned.
Wnt/β-catenin is involved in virtually every aspect of embryonic de-
velopment and in the pathogenesis of many human diseases (Clevers,
2006), and is also involved in homeostatic self-renewal in adult tissues,
such as liver and lung repair following an injury (Monga, 2011; Beers
and Morrisey, 2011). Recently, Wnt/β-catenin has been reported to be
associated with organ ﬁbrosis (Dees and Distler, 2013; Chilosi et al.,
2003) suggesting that they may be new therapeutic targets in liver ﬁ-
brosis (Cheng et al., 2008). Hepatic stellate cells (HSCs) represent a
major ﬁbrogenic cell type in the liver (Bataller and Brenner, 2005). Fol-
lowing a liver injury, HSCs undergo an activation process and change
their phenotype from quiescent retinoid storing HSCs to collagen-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Wnt signaling is stimulated in activated HSCs compared to quiescent
cells, and the inhibition of Wnt signaling by the transduction of the
adenoviral Wnt co-receptor antagonist Dickkopf-1 restores HSC quies-
cence and increases apoptosis in cultured HSCs (Cheng et al., 2008).
Macrophages may perform both injury-inducing and repair-promoting
tasks simultaneously in an injured organ. The depletion of liver macro-
phages aggravates hepatocellular damage, while suppressing liver
ﬁbrosis following bile duct ligation (BDL) (Osawa et al., 2010). More-
over, the depletion of macrophages decreases myoﬁbroblasts in a liver
tumor (Osawa et al., 2013b). By contrast, macrophage depletion during
the ﬁbrosis resolution period induces the failure of matrix degradation
(Dufﬁeld et al., 2005), suggesting that hepaticmacrophages are involved
in the regression of hepatic ﬁbrosis (Friedman, 2005). The roles of β-
catenin in macrophages have been reported. Macrophage-speciﬁc
knockdown of β-catenin causes insufﬁcient skin wound healing due to
defects inmigration, in the adhesion to ﬁbroblasts, and in TGF-β produc-
tion (Amini-Nik et al., 2014).
Following activation by upstream signaling from Wnt, β-catenin
translocates to the nucleus. Nuclear β-catenin recruits the Kat3 tran-
scriptional co-activators, cAMP-response element-binding protein
(CREB)-binding protein (CBP) (Takemaru and Moon, 2000) or EP300
(p300) (Hecht et al., 2000), to stimulate the transcription of its target
genes, and distinct roles have been reported for CBP and p300. CBP/β-
catenin-mediated transcription is critical for proliferation/non-
differentiation, whereas p300/β-catenin-mediated transcription initi-
ates differentiation (Teo and Kahn, 2010; Lenz and Kahn, 2014). ICG-
001, a selective inhibitor of the CBP/β-catenin interaction, attenuates
bleomycin-induced lung ﬁbrosis and reverses the established ﬁbrosis
(Henderson et al., 2010). ICG-001 also ameliorates renal interstitial ﬁ-
brosis induced by unilateral ureteral obstruction (Hao et al., 2011). C-
82 is a second-generation speciﬁc CBP/β-catenin antagonist developed
by Prism Pharma, which inhibits the binding between β-catenin and
CBP and increases the binding between β-catenin and p300 similar to
ICG-001. PRI-724 is phosphorylated-C-82 and is rapidly hydrolyzed to
its active form C-82 in vivo, and pre-clinical studies have shown a very
acceptable toxicity proﬁle (Lenz and Kahn, 2014). A phase I safety
study for hepatitis C virus (HCV)-related cirrhosis patients has been on-
going in our hospital since September 2014. To attempt to clarify the
precise roles of CBP/β-catenin on liver ﬁbrosis, in this study, we investi-
gated the effects of PRI-724 and of its active form, C-82, on chronic liver
injury mouse models and primary isolated mouse HSCs.2. Material and Methods
2.1. Animals and Treatments
Malewild-type (C57BL/6 andBalb/c)mice aged8 to 11weeks or 6 to
9 months were obtained from Japan SLC (Shizuoka, Japan). CCl4 admin-
istration or BDL induced liver ﬁbrosismodelwas used for this study. The
animals were intraperitoneally injected with 1 ml/kg body weight of
CCl4 (1:4 v/v in mineral oil) (Sigma-Aldrich, St. Louis, MO, USA) twice
a week. As a BDL model, common BDL is the most established model.
However, the mortality of mice operated with common BDL was high
at 5 weeks after the surgery. Thus, our established model, partial bile
duct ligation (PBDL) was performed as previously reported (Osawa
et al., 2010; Osawa et al., 2006). The left hepatic duct was ligated with
6-0 silk after anesthesia. The animals were intraperitoneally injected
with or without 0.4 mg/mouse PRI-724 (Prism Pharma, Tokyo, Japan)
dissolved in PBS 4 times aweek. The experimentswere conducted in ac-
cordancewith the institutional guidelines (Guide for the Care andUse of
Laboratory Animals prepared by the National Academy of Sciences) and
the protocol was approved by the Research Committee of Komagome
Hospital. All surgery was performed under anesthesia, and all efforts
were made to minimize suffering.2.2. Isolation of Mouse Primary HSCs
Mouse primary HSCs were isolated as previously described with
slight modiﬁcations (Osawa et al., 2013a). The liver of C57BL/6 male
wild-type or GFP mouse expressing EGFP ubiquitously under the CAG
promoter (chickenβ-actin promoter, rabbitβ-globin poly A, CMV-IE en-
hancer) (8–11week-old or 6–9month-old) was perfused via the inferi-
or vena cava with collagenase (Wako, Osaka, Japan) and pronase E
(EMD Chemicals, Gibbstown, NJ, USA). After digestion, the cell suspen-
sion was ﬁltered through nylon mesh and puriﬁed via 8.2% Nycodenz
(Axis-Shield, Oslo, Norway) gradient centrifugation. The quiescent
HSCs were obtained from normal liver and the in vivo stimulated HSCs
were from ﬁbrotic liver induced by eight week treatment of CCl4. The
isolated HSCs were cultured in uncoated plastic dishes or thin layer
matrigel (Corning, corning, NY, USA) coated dishes with DMEM high
glucose (Wako) supplementedwith 10% fetal bovine serum, 10mM so-
dium pyruvate (Invitrogen, Carlsbad, CA, USA), MEM Non-essential
amino acids (Invitrogen), 15 mM HEPES, and antibiotic solution at 37
°C in 5% CO2. After plating for 12 h (day 0), the quiescent HSCs were
treated with or without C-82 (10 μM, Prism Pharma) dissolved in di-
methyl sulfoxide (DMSO), and replacement of medium (C-82 or
DMSO) was performed in every 5 days. The purity of HSCs was al-
ways 95% as determined by their typical shape and abundant lipid
droplets. As necessary, the cells were ﬁxed with ice-cold methanol
and cell number per low magniﬁcation ﬁeld was determined by nu-
clear counting with 4′,6-diamidino-2-phenylindole (DAPI) staining.
Activated HSCs were obtained by continuous culture of quiescent
HSCs for more than 20 days with replacement of medium in every
5 days. The culture-activated HSCs were treated with or without
C-82. Medium change was not performed after C-82 treatment.
Cell viability was examined using XTT based Cell Proliferation Kit
(Biological Industries, Kibbutz Beit Haemek, Israel). Cell death was
detected by propidium iodide staining, and morphological changes
in the nuclei of cells undergoing apoptosis were determined by
DAPI staining.
2.3. Isolation of Mouse Intrahepatic Leukocytes (IHLs)
IHL isolation was performed as previously reported (Kimura
et al., 2011). Brieﬂy, single-cell suspensions were prepared from
the median lobe of the liver by digestion in RPMI 1640 (Wako) con-
taining 0.02% collagenase IV and 0.002% DNase I (Sigma-Aldrich) for
40min at 37 °C. The cells were overlaid on LympholyteM (Cedarlane,
Westbury, NY, USA) in PBS. After density separation, the isolated
IHLs were used for ﬂuorescence activated cell sorting (FACS) analysis
and RNA extraction.
2.4. Gelatin Zymography
Gelatin zymography was performed with extracted proteins from
the liver as described previously (Wielockx et al., 2001).
2.5. Statistical Analysis
Data are expressed as themean±SDof data collected from at least 3
independent experiments. Data between groups were analyzed by the
2-tailed Student's t-test. A P value of less than 0.05 was an indication
of statistical signiﬁcance.
2.6. Other Experimental Procedures
Other experimental procedures are described in the Supplementary
experimental procedures. These include histological analysis, Western
blot, hydroxyproline measurement, quantitative real time RT-PCR,
FACS analysis, microarray analysis, measurement of serum MMP-9
and TIMP-1, and structure information of PRI-724 and C-82.
Fig. 1. Inhibition of CBP/β-catenin reduced liver ﬁbrosis induced by CCl4. C57BL/6 male mice (8–11 week-old) were treatedwith CCl4 (1 ml/kg (1:4 v/v inmineral oil), twice a week) plus
PRI-724 (0.4 mg/mouse, four times a week) or PBS for four weeks. (A) The protein extracts from the livers were subjected to SDS-PAGE, and immunoblotting was performed with anti-
S100A4, αSMA, and GAPDH antibodies. (B, C) Collagen deposition was assessed by Sirius Red staining (B, upper panel) and by the measurement of the hydroxyproline content (C). The
expression of αSMA was examined by immunohistochemistry with an anti-αSMA antibody (B, lower panel) (original magniﬁcation ×42; graph on right panel). The results shown are
representative of at least three independent experiments. Data are mean ± SD from at least 3 independent experiments. *, P b 0.05 using a 2-tailed Student's t-test.
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3.1. Role of CBP/β-Catenin in Liver Fibrosis
To examine whether CBP/β-catenin is involved in liver ﬁbrosis, CCl4
was administrated to mice and the effect of PRI-724 was investigated.
Following the administration of CCl4 to C57BL/6 (Fig. 1, Supplementary
Fig. 1A, B) or Balb/c male mice (Supplementary Fig. 1C, D, E) (8–11
week-old), the nuclear translocation of β-catenin was observed in the
non-parenchymal cells of the liver (Supplementary Fig. 1A; upper
panel, C; left upper panel). Similarly, S100A4 expression, which is
controlled by CBP/β-catenin and promotes liver ﬁbrosis (Chen et al.,
2015), was increased in non-parenchymal cells following the ad-
ministration of CCl4, and this induction was reduced by the co-
administration of PRI-724 (Fig. 1A, Supplementary Fig. 1A; lower panels,
C; right upper and lower panels). Liver ﬁbrosis was induced in CCl4-
treated mice, as demonstrated by Sirius Red staining, the hydroxypro-
line content, and expression of αSMA, and PRI-724-treated mice
showed a reduction in ﬁbrosis (Fig. 1A, B, C, Supplementary Fig. 1D,
E). Liver ﬁbrosis is induced by hepatocyte damage followed by inﬂam-
matory cell inﬁltration with impaired hepatocyte regeneration. To in-
vestigate whether the reduction of liver ﬁbrosis by PRI-724 is due to
inhibition of hepatocellular damage, serum ALT levels were measured,
which is contained mainly in the hepatocytes and is released into the
bloodstream during hepatocellular damage. As shown in Supplementa-
ry Fig. 1B, ALT elevation by CCl4 treatment was not affected by PRI-724
suggesting that hepatocellular damage was not affected by PRI-724
treatment. PRI-724 alone had no effect on Sirius Red staining and
αSMA expression (data not shown). These results suggest that CBP/β-
catenin is activated in the non-parenchymal cells during ﬁbrosis, and
that this activation promotes liver ﬁbrosis.3.2. Effect of CBP/β-Catenin Inhibition on HSC Activation
To explore the mechanism underlying the inhibitory effect of PRI-
724 on liver ﬁbrosis, we focused on HSCs, which represent a major
ﬁbrogenic cell type in the liver (Bataller and Brenner, 2001), andwe ex-
amined the effects of C-82 (active form of PRI-724) on their activation.
The isolated quiescent HSCs from C57BL/6 male mice (8–11 week-old)
proliferated and displayed a stellate-shaped morphology (Fig. 2A, B,
Supplementary Fig. 2A) during their activation on plastic dishes, accom-
panied by decreased lipid droplets containing vitamin A autoﬂuores-
cence (data not shown). TCF/β-catenin-mediated molecule Cyclin D1,
which is classical readout of β-catenin signaling, was increased during
HSC activation, and C-82 inhibited the induction (Fig. 2C) suggesting
that β-catenin signaling is activated in HSCs during their activation
and C-82 inhibits the β-catenin signaling. In addition to themorpholog-
ical changes, the protein expression of αSMA, and proliferation-related
markers Ki67 and PCNA (Fig. 2C) and the mRNA expression of the
ﬁbrosis-related markers collagen α1(I), αSMA, TIMP-1, and SPARC
were induced in HSCs during their activation (Fig. 2D). C-82 treatment
suppressed these activation-related effects, and the removal of C-82
rapidly restored the features of HSC activation (Supplementary Fig.
2B). Microarray analysis revealed that C-82 treatment inhibited most
of up-regulated gene expression by HSC activation (Supplementary
Fig. 3). The HSCs grown on plastic dishes may not retain the phenotype
as they as when situated in the extracellular matrix (ECM) of the liver
tissue. To bettermimic the in vitro setting, the isolatedHSCswere plated
on the thin layer matrigel. The cells displayed similarmorphology (stel-
late-shaped) as that of cells on the plastic dish, and C-82 treatment sup-
pressed this morphological change (data not shown). In addition, the
in vivo stimulated HSCs were isolated from ﬁbrotic liver by eight week
treatment of CCl4. The cells were rapidly displayed the activated
Fig. 2. Inhibition of CBP/β-catenin suppressed HSC activation. Isolatedmouse primary quiescent HSCs from C57BL/6 mice (8–11week-old) were plated on plastic dishes and treated with
or without C-82 (10 μM). The morphology of the cells was observed at the indicated time periods by phase-contrast microscopy (original magniﬁcation ×200) (A). The cells were ﬁxed
with ice-coldmethanol and stained by DAPI. Cell number per lowmagniﬁcation ﬁeld (original magniﬁcation ×42)was determined by nuclear counting (B). The protein extracts from the
cells were subjected to SDS-PAGE, and immunoblottingwas performedwith anti-Cyclin D1,αSMA, Ki67, PCNA, andGAPDH antibodies (C). The expression of the indicatedmRNA variants
in the cells at day 3 was determined by quantitative real-time RT-PCR (D). The results shown are representative of at least three independent experiments. Data are mean ± SD from at
least 3 independent experiments. *, P b 0.05 using a 2-tailed Student's t-test.
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Fig. 4A). C-82 treatment also suppressed the activation-related effects
(Supplementary Fig. 4A, B) in the in vivo stimulated HSCs, and the re-
moval of C-82 rapidly restored the features of activation (Supplementa-
ry Fig. 4C). Because the young animals (8–11 week-old) may not
represent age of the population that develop liver ﬁbrosis, the effects
of PRI-724 on grown C57BL/6 male mice (6–9 month-old) were exam-
ined. Similar to the young animals, the liver ﬁbrosis induced by CCl4
was reduced by the co-administration of PRI-724 in the case of the
aged animals as demonstrated by Sirius Red staining (Supplementary
Fig. 4D). In addition, C-82 treatment also suppressed the activation-
related changes of gene expression and morphology in the isolated
HSCs from aged animals (Supplementary Figs. 3, 4E). These results sug-
gest that CBP/β-catenin promotes HSC activation. As the levels of TGF-β
mRNA were comparable in all groups (Fig. 2D), the effect of C-82 does
not appear to occur through regulation of TGF-β induction.
3.3. Cell Death Induction of Activated HSCs by Inhibition of CBP/β-Catenin
As described above, PRI-724 suppressed liver ﬁbrogenesis, at least in
part, though the inhibition of HSC activation. To address the consider-
ations that arise in the clinical use of PRI-724 to treat liver cirrhosis pa-
tients, the effect of the reagent on an established ﬁbrotic liver was
examined. Liver ﬁbrosis was induced by the administration of CCl4 for
four weeks, or by PBDL surgery for 2 weeks, in C57BL/6 male mice (8–
11 week-old), after which PRI-724 co-treatment begun. The PRI-724-
treated mice showed reduced liver ﬁbrosis in both the CCl4 model at
eight weeks and in the PBDL model at ﬁve weeks accompanied by
S100A4 reduction (Supplementary Fig. 5A, B), suggesting that PRI-724
is beneﬁcial in the treatment of existing ﬁbrosis. It has been previously
reported that HSC apoptosis (Iredale et al., 1998; Wright et al., 2001)and the reversal of HSC activation (Troeger et al., 2012) contribute to ﬁ-
brosis resolution. To investigate the effect of CBP/β-catenin inhibition
on activated HSCs, C-82 was administered to activated HSCs obtained
by culture on plastic dishes for more than 20 days. After treatment,
the cells changed their shapes from stellate-like to shrunken (Fig. 3A),
and cell viability was reduced (Fig. 3B). The mRNA expression of the
ﬁbrosis-related makers was decreased three days following C-82 treat-
ment (Fig. 3C). Seven days following C-82 administration, the cells
started to detach from the dishes and propidium iodide (Fig. 3A) stain-
ing revealed that cell deathwas induced in these cells. Apoptotic nuclear
segmentation was found in the dead cells examined with DAPI staining
(Supplementary Fig. 6A). The mRNA expression of survivin, which is
regulated by CBP/β-catenin and protects ﬁbroblasts from apoptosis
(Sisson et al., 2012), was increased in the activated HSCs compared to
quiescent cells, whereas C-82 treatment decreased the expression of
this survival gene. In addition, the induction of TUNEL positive apoptotic
non-parenchymal cells was higher following the administration of CCl4
plus PRI-724 than CCl4 plus PBS (Supplementary Fig. 6B). To investigate
the effects of C-82 on cell death in the quiescent HSCs, serial cell toxicity
assays using PI staining were performed from day 0 quiescent HSCs to
day 20 activated HSCs. In contrast to the effects against activated
HSCs, C-82 did not induce cell death in the quiescent HSCs (Fig. 3A, Sup-
plementary Fig. 6C). These results suggest that CBP/β-catenin inhibition
partially reduces an established liver ﬁbrosis through the induction of
cell death in activated HSCs.
3.4. Acceleration of Fibrosis Resolution Through CBP/β-Catenin Inhibition
As described above, C-82 induced cell death in the activated HSCs,
which contributed to liver ﬁbrosis resolution. Next, the effect of PRI-
724 during ﬁbrosis resolution was investigated. Liver ﬁbrosis was
Fig. 3. Inhibition of CBP/β-catenin induced cell death in activated HSCs. Activated HSCs were prepared by the continuous culture of quiescent HSCs from C57BL/6 male mice (8–11week-
old) on plastic dishes formore than20days. The activatedHSCswere treatedwith orwithout C-82 (10 μM) for the indicated time periods. (A) Themorphology of the cellswas observed by
phase-contrast microscopy (original magniﬁcation ×42). The necrotic cells were stained with propidium iodide and observed by ﬂuorescent microscopy (original magniﬁcation ×42).
(B) Cell viability at the indicated periods of time was assessed using XTT based cell viability assay. (C) The expression of the indicatedmRNA variants in the cells at day 3 was determined
byquantitative real-time RT-PCR. (D) ThemRNA levels of survivin in the quiescent or activatedHSCs, treatedwith orwithout C-82 (10 μM),were determined by quantitative real-time RT-
PCR. The results shown are representative of at least three independent experiments. Data aremean± SD from at least 3 independent experiments. *, P b 0.05 using a 2-tailed Student's t-
test.
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and three days after the last CCl4 injection, PRI-724 treatment was
started. The extent of liver ﬁbrosis was decreased two weeks after the
last round of CCl4 administration, and PRI-724 accelerated the resolu-
tion of ﬁbrosis (Fig. 4A, B; left panel), although there was no signiﬁcantFig. 4. Inhibition of CBP/β-catenin accelerated ﬁbrosis resolution. C57BL/6 male mice (8–11 w
weeks. The animalswere then treatedwith orwithout PRI-724 (0.4mg/mouse, four times awee
magniﬁcation ×42; graph on themiddle panel) and by themeasurement of the hydroxyproline
quantitative real-time RT-PCR (B, right panel). (C) The expression of αSMA was examined by
least three independent experiments. Data are mean ± SD from at least 3 independent experidifference at oneweek (data not shown). As both the expression levels of
collagen α1(I) mRNA and of the αSMA protein induced by CCl4 were
strongly decreased only two weeks after the last round of CCl4 adminis-
tration (Fig. 4B: right panel, C),we hypothesized the existence of another
mechanism that contributes to ﬁbrosis resolution, besides the inhibitioneek-old) were treated with CCl4 (1 ml/kg (1:4 v/v in mineral oil), twice a week) for eight
k) for twoweeks. (A, B) Collagendepositionwas assessed by Sirius Red staining (A, original
content (B, left panel). ThemRNA levels of collagenα1(I) in the liver were determined by
Western blotting with an anti-αSMA antibody. The results shown are representative of at
ments. *, P b 0.05 using a 2-tailed Student's t-test.
Fig. 5.Macrophages increased inﬁbrotic liver and sustained during resolution. C57BL/6malemice (8–11week-old)were treatedwith CCl4 (1ml/kg (1:4 v/v inmineral oil), twice aweek)
for eight weeks. The animals were then treatedwith orwithout PRI-724 (0.4 mg/mouse, four times a week) for the indicated periods of time. (A, B, D) IHLswere isolated from themedian
lobe of the animals' livers. The expression of the indicated cell-surfacemakers on the cells was determined by a FACS analysis (A, B). The expression of the indicatedmRNA variants in the
liver (C) and in the isolated IHLs (D) was determined by quantitative real-time RT-PCR. The results shown are representative of at least three independent experiments. Data aremean±
SD from at least 3 independent experiments. *, P b 0.05 using a 2-tailed Student's t-test.
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has been previously reported that the CD11b+ F4/80+ Ly6Clow macro-
phage subset is responsible for ﬁbrosis resolution (Ramachandran
et al., 2012). In accordance with this report, a ﬂow cytometric analysis
of isolated IHLs and immunohistochemistry revealed that the amount
of F4/80+ CD11b+ and Ly6Clow CD11b+ cells was increased following
the administration of CCl4 for eight weeks, and was sustained during ﬁ-
brosis resolution (Fig. 5A, Supplementary Fig. 7). By contrast, the induc-
tion of Gr-1+ CD11b+ and Ly6Chigh CD11b+ cells rapidly decreased
during ﬁbrosis resolution. PRI-724 treatment increased the mRNA ex-
pression of CXCL-1 and CXCL-2, which are macrophage-producing
chemokines, in the liver during ﬁbrosis resolution one week following
the last round of CCl4 administration (Supplementary Fig. 7D), suggest-
ing that this reagent affects liver macrophages. The classically activated
M1 macrophages that suppress the ﬁbrotic activities of ﬁbroblastsFig. 6. Inhibition of CBP/β-catenin increased the expression ofMMPs in IHLs during ﬁbrosis reso
for eight weeks. The animals were then treated with or without PRI-724 (0.4 mg/mouse, four t
was measured by gelatin zymography (A). The expression of MMP-8 in the liver was examine
mRNA variants in the liver (C) and in the isolated IHLs (E) was determined by quantitative real-
shown are representative of at least three independent experiments. Data are mean ± SD from(Huang et al., 2012; Song et al., 2000) as well as the regulatory M2mac-
rophages both have ﬁbrotic (Song et al., 2000) and anti-ﬁbrotic (Pesce
et al., 2009; Wynn and Ramalingam, 2012) features. In this study, most
of the CD11b+ cells in the IHLs from the CCl4-treated liver were
CD206− cells (Fig. 5B), suggesting that the macrophages induced upon
CCl4 administration are M1 macrophages. Similarly, the mRNA expres-
sion level of the M1 marker CD11c was increased in both liver tissues
(Fig. 5C) and in IHLs isolated from the liver (Fig. 5D) following the ad-
ministration of CCl4 for eight weeks, and were sustained during ﬁbrosis
resolution. PRI-724 treatment did not affect the mRNA expression of
CD11c, suggesting that the reagent has no effect on the induction of
M1macrophages. By contrast, the number of CD11b+ CD206+M2mac-
rophages was very low compared to M1 macrophages (Fig. 5B), and
mRNA expression of the M2 marker CD163 did not increase during
liver ﬁbrosis and the resolution of ﬁbrosis (Fig. 5C, D), suggesting thelution. C57BL/6malemice (8–11week-old)were treatedwith CCl4 (1ml/kg, twice aweek)
imes a week) for one week. The collagenase activity in the protein extracts from the livers
d by Western blotting with an anti-MMP8 antibody (B). The expression of the indicated
time RT-PCR. The ratio of serumMMP-9/TIMP-1was determined by ELISA (D). The results
at least 3 independent experiments. *, P b 0.05 using a 2-tailed Student's t-test.
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ﬁcations (Ly6Chigh/low or M1/2) are completely overlapping, IHLs from
the CCl4-treated liver were analyzed. Both of Ly6Chigh and Ly6Clow cells
contained CD206− cells (data not shown), suggesting that these two
are non-overlap classiﬁcations.
Macrophages have been reported to produce MMPs (Huang et al.,
2012; Song et al., 2000; Shapiro et al., 1993), which are involved in ﬁ-
brosis resolution (Wick et al., 2013; Pellicoro et al., 2014). Because
MMP induction should be prior to resolution, the MMPs were analyzed
at one week after CCl4 treatment for eight weeks. Gelatin zymography
showed that the activation of MMP-9 in the liver was accelerated by
PRI-724 during liver resolution (Fig. 6A). Similarly, the induced levels
of protein expression of MMP-8 and mRNA expression of MMP-9, -2
and -8 in the liver were higher in PRI-724-treated animals (Fig. 6B, C).
By contrast, MMP-13 and TIMP-1, an endogenous inhibitor of MMPs,
were not affected by PRI-724. Moreover, the ratio of serum MMP-9/
TIMP-1 was increased in PRI-724-treated animals (Fig. 6D). These re-
sults suggest that the acceleration of ﬁbrosis resolution by PRI-724
may occur through changing in balance between MMPs and TIMP-1,
and the effects may result in the ﬁbrosis resolution at two weeks after
CCl4 treatment. In isolated IHLs, S100A4 mRNA expression was in-
creased by liver ﬁbrosis, and this induction was suppressed by PRI-724
(Fig. 6E), suggesting that CBP/β-catenin was activated in IHLs and that
the reagent affected this activation. Similar to the liver, the mRNA ex-
pression of MMP-9, -2, and -8 was increased in IHLs during ﬁbrosis res-
olution, and PRI-724 accelerated the induction of MMPs. These results
suggest that the enhanced production of MMPs from the M1 macro-
phages may be involved in the acceleration of ﬁbrosis resolution by
PRI-724.
4. Discussion
The present study investigated the contribution of CBP/β-catenin to
the progression of liver ﬁbrosis in mice. The results, which suggest that
the inhibition of CBP/β-catenin suppresses liver ﬁbrosis through the in-
hibition of HSC activation, the activated HSC death, and the production
of MMPs frommacrophages, provide novel therapeutic possibilities for
the treatment of liver ﬁbrosis.
In the injured liver, the initial hepatocyte cell death stimulates sub-
sequent inﬂammatory responses, leading to further liver injury and ﬁ-
brosis. HSC activation and ﬁbrogenesis are mediated by a complex
cross-talk between damaged parenchymal and non-parenchymal cells,
such as Kupffer cells, which activate HSCs through TGF-β production
(Bataller and Brenner, 2005). In the CCl4- or BDL-induced liver injury
model, the translocation of β-catenin and S100A4 expression were ob-
served only in the non-parenchymal cells. In addition, PRI-724 did not
affect the liver injuries examined histologically and biochemically.
These results suggest that β-catenin is not involved in hepatocyte cell
death. Moreover, the co-administration of PRI-724 had no effect on
the number of F4/80-positive cells in the liver of CCl4-treated mice
(data not shown), and C-82 treatment suppressed the activation of qui-
escent HSCs on the plastic dishes, suggesting that the inhibitory effect of
PRI-724 on ﬁbrogenesis is due to its direct effect on HSCs.
It has been reported that the levels of the β-catenin protein are ele-
vated in ﬁbroblasts during proliferation, that stabilized β-catenin-
expressing mice show aggressive ﬁbromatoses and hyperplastic cuta-
neous wounds (Cheon et al., 2002), and that Wnt signaling is required
for TGF-β-mediated ﬁbrosis to occur (Akhmetshina et al., 2012). In pro-
genitor cells, the selective blocking of the CBP/β-catenin interaction by
ICG-001 initiates a differentiation program (Lenz and Kahn, 2014).
Thus, it is likely that C-82 shifts the balance from CBP/β-catenin to
p300/β-catenin-mediated transcription, resulting in the induction of
differentiation rather than proliferation, through which activation was
inhibited in the quiescent HSCs. The death of activated HSCs has been
reported to contribute to ﬁbrosis resolution (Iredale et al., 1998;
Wright et al., 2001; Issa et al., 2001), and the inhibition ofWnt signalingincreases apoptosis in cultured HSCs (Cheng et al., 2008). In the acti-
vated HSCs, C-82-induced cell death is observed seven days after the
beginning of the treatment. On the other hand, C-82 did not induce
cell death in the quiescent HSCs for at least 15 days (data not
shown), and the removal of C-82 started its activation. These results
suggest that CBP/β-catenin inhibition induces cell death only in acti-
vated HSCs, but not in quiescent cells. During the activation, CBP/β-
catenin-mediated transcription, such as that of survivin is increased
and these transcripts may be required for the survival of activated
HSCs.
The contribution of macrophages to ﬁbrosis resolution has been re-
ported (Dufﬁeld et al., 2005; Friedman, 2005). MMPs resolve the ECM
resulting in ﬁbrosis resolution (Iimuro and Brenner, 2008), and macro-
phages have been reported to produce MMPs (Huang et al., 2012; Song
et al., 2000; Shapiro et al., 1993). The cell count of macrophages in the
liver during ﬁbrosis resolution was comparable in PRI-724-treated and
untreated mice, suggesting that the reagent affects the property, but
not the number, of cells. In prostate cancer PC3 cells, p300 knockdown
by siRNA leads to decreased MMP-9 activity, accompanied by the de-
creased mRNA expression of MMP-9 and MMP-2 (Santer et al., 2011),
suggesting that p300/β-catenin is involved in MMP expression. Thus,
PRI-724may shift the balance to p300/β-catenin transcription resulting
inMMP expression. The expression of MMP-8, generally known as neu-
trophil collagenase, was also up-regulated by PRI-724. The neutrophil-
dependent resolution of the repair of the cholestatic rat liver has been
reported (Harty et al., 2008). However, Gr-1-positive cells, which indi-
cate the presence of neutrophils, rapidly disappeared during ﬁbrosis
resolution. Besides neutrophils, MMP-8 expression is found in other in-
ﬂammatory cells such as monocytes and macrophages (Prikk et al.,
2002), plasma cells (Wahlgren et al., 2001), and T-cells (Kim et al.,
2001), suggesting that neutrophils may play aminor role in the acceler-
ation of ﬁbrosis resolution by PRI-724.
These data do not provide evidence that the MMP production from
macrophages is directly regulated by CBP/β-catenin and that the pro-
ducedMMPs are involved in ﬁbrosis resolution in ourmodel. The gating
strategy formacrophages in analysis of IHL does not excludemonocytes.
Moreover, the mechanism by which CBP/β-catenin stimulates the acti-
vation of quiescent HSCs and induces the survival of activated HSCs re-
mains unclear. The effects of CBP/β-catenin inhibitors against portal
ﬁbroblasts, which represent another type of collagen-producing cells
besides HSCs in biliary ﬁbrosis (Wells, 2014), have not yet been investi-
gated. In addition, it is still unclear if the effects of the CBP/β-catenin in-
hibitor are primarily on HSCs, macrophages, other immune cells, and/or
sinusoidal endothelium in vivo. Thus, further studies are needed to re-
solve these uncertainties.
5. Conclusions
The inhibition of CBP/β-catenin suppressed liver ﬁbrogenesis and
promoted ﬁbrosis resolution. Thus, targeting CBP/β-catenin may repre-
sent a new therapeutic strategy in the treatment of liverﬁbrosis, and the
phase I clinical study of PRI-724 on HCV-related liver cirrhosis patients
is ongoing in our hospital.
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